




More of the Solution

Joshua M. Sharfstein, M.D.
Johns Hopkins Bloomberg School of Public Health

March 2022

CDC: 104,288 Fatal Overdoses

Figure 1b. Percent Change in Predicted 12 Month-ending Count of Drug Overdose Deaths, by Jurisdiction: September 2020 to September 2021



Select predicted or reported number of deaths


- Predicted
- Reported

Percent Change for United States

15.9



Legend for Percent Change in Drug Overdose Deaths Between 12-Month Ending Periods




“We started it”: Atul Gawande on doctors’ role in the opioid epidemic

By Sarah Kliff | sarah@vox.com | Updated Sep 8, 2017, 5:25pm EDT




1992-2011: Nearly 10-fold increase in Opioids Dispensed



Source: IQVIA, MME basis



Initial Wave: Prescription Opioid Overdoses




All Opioid
Overdoses


Prescription
Opioid Overdoses



Too Late, a Crisis Is Recognized




...And Then?



prescribing falls

&



deaths rise




Drug users switch to heroin
because it's cheap, easy
to get



It's not enough to be
less of the problem.



More of the Solution: Effective Treatment



Topics

1. Medication for Opioid Use Disorder Saves Lives
2. There Are Too Few Prescribers
3. How Boards Can Be More of the Solution




Topics

1. Medication for Opioid Use Disorder Saves Lives
2. There Are Too Few Prescribers
3. How Boards Can Be More of the Solution



How do medications for opioid addiction work?

Medications for Opioid Use Disorder



All 3 medications work at the level of the opioid receptors to reduce cravings.

None of the medications produce euphoria for patients at therapeutic doses.


None of the medications produce fatigue at therapeutic doses.

Using medications as treatment is not addiction.

What's the evidence in support of medication treatment?

	Depot Naltrexone	Buprenorphine	Methadone
Reduces Cravings	✓	✓	✓
Reduces Misuse	✓	✓	✓
Reduces Overdose		✓	✓
Reduces Infectious Disease		✓	✓
Reduces Mortality		✓	✓
Increases Employment		✓	✓
Reduces Criminality			✓
Track record > 20 years			✓

Maryland: **80% Reduction** in Overdose Fatality Risk With Methadone and Buprenorphine



ADDICTION

SSA SOCIETY FOR THE STUDY OF ADDICTION

Research Report | [Full Access](#)

Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services

Noa Krawczyk, Ramin Mojtabai, Elizabeth A. Stuart, Michael Fingerhood, Deborah Agus, B. Casey Lyons, Jonathan P. Weiner, Brendan Saloner



Baltimore City: Major Decline in Overdose as Treatment ↑




FIGURE 1—Heroin overdose deaths and opioid agonist treatment: Baltimore, MD, 1995–2009.

Opioid Agonist Treatments and Heroin Overdose Deaths in Baltimore, Maryland, 1995–2009

Robert P. Schwartz, MD, Jan Gryczynski, PhD, Kevin E. O'Grady, PhD, Joshua M. Sharfstein, MD, Gregory Warren, MA, MBA, Yngvild Olsen, MD, Shannon G. Mitchell, PhD, and Jerome H. Jaffe, MD



Topics

1. Medication for Opioid Use Disorder Saves Lives
2. There Are Too Few Prescribers
3. How Boards Can Be More of the Solution



Too Few Prescribers in Outpatient Treatment

- **40% of US counties** do not have a single waived buprenorphine provider in 2018.
- Among 1,100 counties with the greatest need for buprenorphine services, 56% likely had inadequate capacity.



U.S. Department of Health and Human Services
Office of Inspector General

Geographic Disparities Affect Access to Buprenorphine Services for Opioid Use Disorder

OEI-12-17-00240
January 2020

oig.hhs.gov

Christi A. Grimm
Principal Deputy Inspector
General



- For residential treatment admissions for opioid use, only **17.7%** received medications in states that expanded Medicaid.
- In states that did not expand Medicaid, the rate of medication treatment was **1.9%.**

Original Investigation | Psychiatry

February 7, 2020

Differences in Availability and Use of Medications for Opioid Use Disorder in Residential Treatment Settings in the United States

Andrew S. Huhn, PhD, MBA^{1,2}; J. Gregory Hobelmann, MD, MPH^{1,2}; Justin C. Strickland, PhD¹; [et al](#)

Too Few Prescribers in Emergency Departments

- More than 1 in 20 patients with nonfatal overdoses will be dead in a year.
- Yet relatively few Emergency Departments routinely offer access to buprenorphine treatment, which dramatically reduces the risk of death.



<http://americanhealth.jhu.edu/addiction-emergency>

BEHAVIORAL HEALTH CARE

By Noa Krawczyk, Caroline E. Picher, Kenneth A. Feder, and Brendan Saloner

DOI: 10.1377/hlthaff.2017.0890
HEALTH AFFAIRS 36,
NO. 12 (2017): 2046–2053
©2017 Project HOPE—
The People-to-People Health
Foundation, Inc.

Only One In Twenty Justice-Referred Adults In Specialty Treatment For Opioid Use Receive Methadone Or Buprenorphine

VIEWPOINT

Confronting the Stigma of Opioid Use Disorder— and Its Treatment

**Yngvild Olsen, MD,
MPH**

Institutes for Behavior
Resources Inc,
Baltimore, Maryland.

**Joshua M. Sharfstein,
MD**

Maryland Department
of Health and Mental
Hygiene, Baltimore.

The death of Philip Seymour Hoffman from a heroin overdose tragically adds another name to the list of celebrities who have lost their lives to addiction. Increasing numbers of overdoses from prescription opioids and a more recent increase in heroin-associated fatalities have caused heartbreak in communities across the country. More than 30 000 deaths from unintentional drug overdose were reported in the United States in 2010, the most recent year for which data are available.¹

treatment approach supported by the same level of evidence.

Nonetheless, there is significant resistance to the treatment of opioid use disorder with medications. For instance, some communities have opposed having medication-assisted treatment services located in their neighborhoods, some local officials have proposed legislation in violation of the Americans with Disabilities Act that would change zoning codes to exclude medication-assisted treatment centers, some health insurers have

"Less than 30% of primary care providers reported they were willing to have a person taking medication for opioid use disorder as a neighbor or marry into their family ... Greater stigma was associated with an 11 percentage point lower likelihood that primary care providers prescribed [medication treatment] and with lower support for policies intended to increase access to [medication treatment]."

The role of stigma in U.S. primary care physicians' treatment of opioid use disorder

Elizabeth M. Stone^{a,b,*}, Alene Kennedy-Hendricks^{a,b}, Colleen L. Barry^{a,b},
Marcus A. Bachhuber^c, Emma E. McGinty^{a,b}

In 2020, 11.2% of people with an opioid use disorder received medication treatment.

NSDUH 2020, Table 5.42B.



Topics

1. Medication for Opioid Use Disorder Saves Lives
2. There Are Too Few Prescribers
3. How Boards Can Be More of the Solution



Board Agenda

1. Educate board members about medication treatment
2. Publicly endorse medication treatment
3. Advocate for training of prescribers in professional schools and residencies
4. Require CE for medication treatment



Board Agenda

5. Make sure health professionals with opioid use disorder have access to lifesaving medication treatments.





2015 Guide:

Participants cannot work while taking medication assisted treatment such as Methadone, Suboxone and other drugs in this class.

2020 Guide:

Participants cannot work while taking medication assisted treatment. Cases will be reviewed by the RAMP team.



The Case for Buprenorphine and Methadone in Professional Programs

1. Saves lives
2. Sustains recovery = better for patient care
3. Respects clinicians



The Case for Buprenorphine and Methadone in Professional Programs

4. Reduces stigma

PERSPECTIVE

PRACTICING WHAT WE PREACH

Practicing What We Preach — Ending Physician Health Program Bans on Opioid-Agonist Therapy

Leo Beletsky, J.D., M.P.H., Sarah E. Wakeman, M.D., and Kevin Fiscella, M.D., M.P.H.



The Case for Buprenorphine and Methadone in Professional Programs

5. Less legal liability

According to the Legal Action Center, it would **violate the Americans with Disabilities Act** for a state licensing board to deny licensure or take disciplinary action against a health care professional because they receive appropriate medication treatment.

It also would be discriminatory for a licensing board to mandate a health professional into a professional assistance program that does not permit appropriate medication treatment.



The Case Against Buprenorphine and Methadone in Professional Programs

1. Not needed as outcomes are terrific as is
2. Impairment
3. Naltrexone is just as good
4. "Even one bad outcome" and it threatens the whole professional program



A Closer Look

"Outcomes are terrific."	Outcomes could be much better, including fewer drop-outs and fewer people dissuaded from even trying to return to work.
Impairment	Mixed evidence on effects, and unlikely to be worse than many other commonly prescribed medications. Best to assess on individual basis.
Naltrexone is just as good.	Evidence for naltrexone much less strong, and regardless, patients should get what's right for them.
"Even one bad outcome."	Every reason to believe medications will lower the number of bad outcomes.





ASAM American Society of
Addiction Medicine

Public Policy Statement on Physicians and other Healthcare Professionals with Addiction



Healthcare professionals should be offered the full range of evidence-based treatments, including medication for addiction, in whatever setting they receive treatment. Regulatory agencies (including state licensing boards), professional liability insurers, and credentialing bodies should not discriminate against the type of treatment an individual receives based on unjustified assumptions that certain treatments cause impairment.



POSITION STATEMENT

ACMT Position Statement: Allow Optimal Treatment for Healthcare Professionals with Opioid Use Disorder

Ryan T. Marino¹ · Meghan Spyres^{2,3} · Timothy J. Wiegand⁴ · Kavita M. Babu⁵ · Andrew Stolbach⁶

Received: 17 September 2021 / Revised: 4 October 2021 / Accepted: 6 October 2021
© American College of Medical Toxicology 2021

Keywords Opioid use disorder · Health care professionals · Physicians · Buprenorphine · Impairment



"Buprenorphine and methadone are lifesaving treatments for opioid use disorder. Health care professionals should have access to the best treatments, including opioid agonist medications."



More of the solution.



Questions?

Acknowledgements:

→ Matthew Salzman, M.D.

